Paradigm Biopharmaceuticals scores A$16m investment—Here’s what it means for osteoarthritis treatment
Paradigm Biopharmaceuticals Ltd. (ASX: PAR) has secured a significant A$16 million in funding, positioning the company to launch its pivotal Phase 3 global clinical trial ... Read More
Recce Pharmaceuticals secures approval for Phase 3 trial of R327G in Indonesia
Recce Pharmaceuticals Limited (ASX: RCE) has achieved a significant milestone in its quest to tackle diabetic foot infections (DFIs), a common complication among diabetes patients. ... Read More
Johnson & Johnson’s CARVYKTI achieves significant milestone in multiple myeloma treatment
Johnson & Johnson (NYSE: JNJ) has recently announced encouraging outcomes from the second interim analysis of the Phase 3 CARTITUDE-4 study, which is pivotal in ... Read More
VectivBio initiates phase 3 trial of apraglutide in patients with short bowel syndrome
VectivBio, a leading Swiss biotechnology firm, has announced the commencement of patient dosing in its phase 3 STARS clinical trial. This trial will evaluate the ... Read More
AgeneBio enrolls first patient in phase 3 trial for AGB101 in MCI due to Alzheimer’s Disease
AgeneBio, a leading biopharmaceutical company specialising in central nervous system (CNS) disorders, has announced the enrolment of the first patient in its pivotal phase 3 ... Read More